1. Home
  2. TMDX vs MIRM Comparison

TMDX vs MIRM Comparison

Compare TMDX & MIRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo TransMedics Group Inc.

TMDX

TransMedics Group Inc.

HOLD

Current Price

$123.69

Market Cap

3.9B

Sector

Health Care

ML Signal

HOLD

Logo Mirum Pharmaceuticals Inc.

MIRM

Mirum Pharmaceuticals Inc.

HOLD

Current Price

$78.82

Market Cap

4.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TMDX
MIRM
Founded
1998
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.9B
4.2B
IPO Year
2019
2019

Fundamental Metrics

Financial Performance
Metric
TMDX
MIRM
Price
$123.69
$78.82
Analyst Decision
Buy
Strong Buy
Analyst Count
8
11
Target Price
$144.25
$92.45
AVG Volume (30 Days)
724.8K
813.7K
Earning Date
10-29-2025
11-04-2025
Dividend Yield
N/A
N/A
EPS Growth
170.70
N/A
EPS
2.54
N/A
Revenue
$566,354,000.00
$471,794,000.00
Revenue This Year
$38.81
$53.78
Revenue Next Year
$20.49
$19.91
P/E Ratio
$48.97
N/A
Revenue Growth
41.20
53.66
52 Week Low
$55.00
$36.88
52 Week High
$156.00
$82.58

Technical Indicators

Market Signals
Indicator
TMDX
MIRM
Relative Strength Index (RSI) 43.84 62.89
Support Level $120.82 $63.23
Resistance Level $133.29 $82.58
Average True Range (ATR) 5.52 3.74
MACD -0.91 1.62
Stochastic Oscillator 19.55 81.03

Price Performance

Historical Comparison
TMDX
MIRM

About TMDX TransMedics Group Inc.

TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System(OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The Company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.

About MIRM Mirum Pharmaceuticals Inc.

Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.

Share on Social Networks: